Form 8-K - Current report:
SEC Accession No. 0001655759-24-000113
Filing Date
2024-07-30
Accepted
2024-07-30 07:33:09
Documents
15
Period of Report
2024-07-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arvn-20240730.htm   iXBRL 8-K 26708
2 EX-99.1 arvn-20240730xexx991.htm EX-99.1 107792
6 image_0.jpg GRAPHIC 32844
  Complete submission text file 0001655759-24-000113.txt   320965

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arvn-20240730.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arvn-20240730_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arvn-20240730_pre.xml EX-101.PRE 13046
17 EXTRACTED XBRL INSTANCE DOCUMENT arvn-20240730_htm.xml XML 2913
Mailing Address 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511
Business Address 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511 203-535-1456
ARVINAS, INC. (Filer) CIK: 0001655759 (see all company filings)

EIN.: 472566120 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38672 | Film No.: 241154395
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)